Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
Authors
Keywords
-
Journal
JAMA Dermatology
Volume -, Issue -, Pages -
Publisher
American Medical Association (AMA)
Online
2021-08-18
DOI
10.1001/jamadermatol.2021.2905
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
- (2021) Kristian Reich et al. LANCET
- Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
- (2021) Kenneth B Gordon et al. LANCET
- Bimekizumab versus Secukinumab in Plaque Psoriasis
- (2021) Kristian Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
- (2020) Christopher T Ritchlin et al. LANCET
- Review of Comorbidities of Hidradenitis Suppurativa: Implications for Daily Clinical Practice
- (2020) Thrasyvoulos Tzellos et al. Dermatology and Therapy
- Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa
- (2019) Christos C. Zouboulis et al. DERMATOLOGY
- Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab
- (2018) A Schuch et al. ACTA DERMATO-VENEREOLOGICA
- Increased Suicide Risk in Patients with Hidradenitis Suppurativa
- (2018) Linnea Thorlacius et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
- (2018) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The IL-1 pathway is hyperactive in Hidradenitis suppurativa and contributes to skin infiltration and destruction
- (2018) Ellen Witte-Händel et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Prevalence and Risk of Inflammatory Bowel Disease in Patients with Hidradenitis Suppurativa
- (2017) Alexander Egeberg et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents
- (2017) Łukasz Matusiak et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Adalimumab for the treatment of hidradenitis suppurativa/acne inversa
- (2016) Christos C. Zouboulis Expert Review of Clinical Immunology
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Unknown
- (2016) JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients
- (2015) Peter Theut Riis et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
- (2015) C.C. Zouboulis et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis
- (2015) L. E. Durham et al. Current Rheumatology Reports
- Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
- (2013) Alexa B. Kimball et al. ANNALS OF INTERNAL MEDICINE
- Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
- (2013) Dominique Baeten et al. LANCET
- Hidradenitis Suppurativa
- (2012) Gregor B.E. Jemec NEW ENGLAND JOURNAL OF MEDICINE
- Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa
- (2011) Christoph Schlapbach et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Hidradenitis Suppurativa
- (2010) F. William Danby et al. DERMATOLOGIC CLINICS
- Regulation of inflammatory responses by IL-17F
- (2008) Xuexian O. Yang et al. JOURNAL OF EXPERIMENTAL MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started